Human antibodies from phage display libraries: Expression of recombinant full length immunoglobulin G specific to the Hepatitis C virus E2 glycoprotein H

New Microbiologica

Volumn 32, Issue 4, 2009, Pages 341-349

  Bugli, Francesca ^a   Graffeo, Rosalia ^a   Pescatori, Mario ^a   Sterbini, Francesco Paroni ^a   Toreiii, Riccardo ^a   Masucci, Luca ^a   Manzara, Stefania ^a   Fadda, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Hepatitis c virus; Human recombinant antibody; Mammalian expression vectors; Phage display

Indexed keywords

GLYCOPROTEIN E2, HEPATITIS C VIRUS; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; PEPTIDE LIBRARY; RECOMBINANT PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; CHO CELL; CRICETULUS; EVALUATION; GENETICS; HAMSTER; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR CLONING;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; CRICETULUS; HEPACIVIRUS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; PEPTIDE LIBRARY; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS;

BACTERIA (MICROORGANISMS); EUKARYOTA; HEPATITIS C VIRUS; MAMMALIA;

EID: 74249120129     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. ABRIGNANI S., ROSA D. (1998). Perspectives for a hepatitis C virus vaccine. Clin. Diagn. Virol. 10 (2-3), 181185.
2. AGARWAL S.K., DASH S.C., GUPTA S., PANDEY R.M. (2009). Hepatitis C virus infection in haemodialysis: the 'no-isolation' policy should not be generalized. Nephron. Clin. Pract. Jan. 111 (2), cl33-cl40.
3. ALLANDER T., DRAKENBERG K., BEYENE A., ROSA D., ABRIGNANI S., HOUGHTON M., WIDELL A., GRILLNER L., MATS A., PERSSON A. (2000). Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. Journal of General Virology. 81, 2451-2459.
4. ALTER M.J., MARGOLIS H.S., KRAWCZYNSKI K., JUDSON F.N., MARES A., ALEXANDER W.J., HU P.Y, MILLER J.K., GERBER M.A., SAMPLINER R.E., ET AL. (1992). The natural history of community acquired hepatitis C in the United States. The sentinel Counties Chronic non-A non-B Hepatitis Study Team. N. Engl. J. Med. 327, 1899-1905.
5. AMES R.S., TORNETTA M.A., DEEN K., JONES C.S., SWIFT A.M., GANGULY S. (1995). Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins. J. Immunol. Methods. 184, 177-186.
6. BUGLI F., MANCINI N., KANG C. Y., DI CAMPU C., GRECO A., MANZIN A., GABRIELLI A., GASBARRINI A., FADDA G., VARALDO P.E., CLEMENTI M., BURIONI R. (2001 Mapping B-cell epitopes og hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display library.J. Virol. 75, 9986-9990. (Pubitemid 32900134)
7. BUGLI E, MANZARA S., TORELLI, R. GRAFFEO, R., SANTANGELO R., CATTANI P., FADDA G. (2004). Human monoclonal antibody fragment specific for glycoprotein G in herpes simplex virus type 2 with applications for seroyipe-specific diagnosis. J. Clin. Microbiol. 42, 1250-1253.
8. BURIONI R., BUGLI F., MANCINI N., ROSA D., DI. CAMPLI C., MORONCINI G., MANZIN A., ABRIGNANI S., VARALDO P.E., CLEMENTI M., FADDA G. (2001). Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology. 288, 29-35.
9. BURIONI R., PLAISANT P., MANZIN A., ROSA D., DELU CARRI V., BUGLI F., SOLFOROSI L., ABRIGNANI S., VARALDO P.E., FADDA G., CLEMENTI M. (1998). Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology. 28, 810-814.
10. BURIONI R., PLAISANT P. BUGLI F. DELLI CARRI V., CLEMENT M., FADDA G. (1998). A vector for the expression of recombinant monoclonal Fab fragments in bacteria. J. Immunol. Methods. 217, 195199.
11. BURTON D.R., BARBAS CE, PERSSON M.A.A., KOENIG S., CHANOCK R.M., LERNER R.A. (1991). A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial li-brades of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA. 88, 10134-10137.
12. CHOO Q.L., Kuo G., RALSTON R., WEINER A., CHIEN D., VAN NEST G., HAN J., BERGER K., THUDIUM K., KUO C., ET AL. (1994). Vaccination of chimpanzees against infection by hepatitic C virus. Proc. Natl. Acad. Sci. USA. 91, 1294-1298. (Pubitemid 24058997)
13. CHOO Q.L., Kuo G., WEINER A.J., OVERBY L.R., BRADLEY D.W., HOUGHTON M. (1989 Isolation of a CDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science. 244, 359-362. (Pubitemid 19117877)
14. COCQUEREL L., VOISSET C., DUBUISSON J. (2006). Hepatitis C virus entry: potential receptors and their biological functions.J. Gen. Virol. 87, 1075-1084.
15. CURRY M.P. (2004). Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 15, 955963.
16. DICKSON R.C (1998). Management of posttransplantation viral hepatitis-hepatitis B. Liver. Transpl. Surg. 4 (5 Suppl 1), S73-78.
17. DUBUISSON J., PENIN F., MORADPOUR D. (2002) Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell. Biol. 12, 517-523. (Pubitemid 35346702)
18. DUBUISSON J. (2007) Hepatitis C virus proteins. World J. Gastroenterol. 13, 2406-2415 Review.
19. FARCI P., ALTER H. J., GOVINDARAJAN S., WONG D.C., MILLER R.H., OGATA N., ET AL. (1992). Lack of protective immunity against reinfection with hepatitis C virus. Science. 258, 135-140.
20. FARCI P., ALTER H.J., WONG D.C, MILLER R.H., GOVINDARAJAN S., ENGLE R., SHAPIRO M., PURCELL R.H. (1994). Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA. 91, 7792-7796.
21. FARCI P., SHIMODA A., WONG D., CABEZON T., DEGIOANNIS D., STRAZZERA A., SHIMIZU Y., SHAPIRO M., ALTER H.J., PURCELL R.H. (1996). Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. USA. 93, 1539415399.
22. IACOBELUS A., IPPOUTO A., ANDRIULU A. (2008). Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J. Gastroenterol 14, 6467-6472.
23. IRSHAD M., KHUSHBOO I, SINGH S., SINGH S. (2008). Hepatitis C virus (HCV): a review of immunological aspects. Int. Rev. Immunol. 27, 497-517.
24. ISHII K., ROSA D., WATANABE Y., KATAYAMA T., HARADA H., WYATT C., KIYOSAWA K., AIZAKI H., MATSUURA Y, HOUGHTON M., ABRIGNANI S., MIYAMURA T. (1998). High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C Hepatology. 28, 1117-1120.
25. Kuo G., CHOO Q.L., ALTER H.J., GITNICK G.L., REDEKER A.G., PURCELL R.H., MIYAMURA T., DIENSTAG J.L., ALTER M.J., STEVENS C.E., ET AL. (1989). An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. Science. 244, 362364.
26. LANFORD R.E., BIGGER C, BASSETT S., KLIMPEL G. (2001). The chimpanzee model of hepatitis C virus infections. ILAR. J. 42, 117-126. (Pubitemid 33708703)
27. LESNIEWSKI R., OKASINSKI G., CARRICK R., VAN SANT C, DESAI S., JOHNSON R., SCHEFFEL J., ET AL. (1995). Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J. Med. Virol. 45, 415-422.
28. MARKOWITZ J.S., MARTIN P., CONRAD A.J., MARKMANN J.E., SEU P., YERSIZ H., Goss J.A., SCHMIDT P., PAKRASI A., ARTINIAN L., MURRAY N.G., IMAGAWA D.K., HOLT C., GOLDSTEIN L.I., STRIBLING R., BUSUTTIL R.W (1998). Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 28, 415-422.
29. MEYER K., BASU A., PRZYSIECKI C.T., LAGGING L.M., DI RISCEGLIE A.M., CONLEY A.J., RAY R. (2002). Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing Hepatitis C virus E2 chimeric glycoprotein. J. Virol. 76, 2150-2158.
30. MONTSERRAT P., MAJOR M. E., MIHALIK K., FEINSTONE S. M. (2004). Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine. 22, 9911000.
31. PERICO N., CATTANEO D., BIKBOV B., REMUZZI G. (2009). Hepatitis C infection and chronic renal diseases. Clin. J. Am. Soc. Nephrol. 4, 207-220.
32. PERSIC L., ROBERTS A., WILTON J., CATTANEO A., BRADBURY A., HOOGENBOOM H.R. (1997). An integrate vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene. 187, 9-18.
33. PIAZZA M., SAGLIOCCA L., TOSONE G., GUADAGNINO V., STAZI M.A., ORLANDO R., BORGIA G., ROSA D., ABRIGNANI S., PALUMBO E., MANZIN A., CLEMENTI M. (1997). Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch. Internal Med. 157, 1537-1544.
34. PILERI P., UEMATSU Y., CAMPAGNOU S., GALU G., FALUGI E., PETRACCA R., WEINER A. J., HOUGHTON M., ROSA D., GRANDI G., ABRIGNANI S. (1998). Binding of hepatitis C virus to CD81. Science. 30, 938-941.
35. PRABHU R., KHALAP N., BURIONI R., CLEMENTI M., GARRY R.F., DAS S. (2004). Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone. Am. J. Pathol. 65, 1163-1173.
36. RATH S., STANLEY C.M., STEWARD M.W. (1988). An inhi- bition enzyme immunoassay for estimating relative antibody affinity and affinity heterogeneity. J. Immunol. Methods. 106, 245-249.
37. ROLUER C., DEPLA E., R. DREXHAGE J. A., VERSCHOOR E. J., VERSTREPEN B. E., FATMI A., BRINSTER C., FOURNILLIER A., WHELAN J. A., WHELAN M., JACOBS, D. MAERTENS G., INCHAUSPÉ G., HEENEY J. L. (2004). Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response.J. Virol. 78, 187-196.
38. ROSA D., CAMPAGNOLI S., MORETTO C., GUENZI E., COUSENS L., CHIN M., DONG C., WEINER A.J., LAU J.Y., CHOO Q.L., CHIEN D., PILERI P., HOUGHTON M., ABRIGNANI S. (1996). A quantitative test to estimate neutralizing antibodies to the hepatitis C virus. Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc. Natl. Acad. Sci. USA. 93 (5), 1759-1763.
39. ROSEN H.R. (2001). Hepatitis B and C in the liver transplant recipient: current understanding and treatment. Liver. Transpl. 7, S87-S98. (Pubitemid 33100358)
40. nd edition. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY.
41. SHIMIZU Y.K., HIJIKATA M., IWAMOTO A., ALTER H.J., PURCELL R.H., YOSHIKURA H. (1994). Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68, 1494-1500.
42. WILLIAMSON R.A., BURIONI R., SANNA P.P., PARTRIDGE L.J., BARBAS C.F., BURTON D.R. (1993). Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc. Natl. Acad. Sci. USA. 90, 4141-4145.
43. WONG J.B., MCQUILLAN G.M., MCHUTCHISON J.G., ET AL. (2000 Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public. Health. 90, 1562-1569. (Pubitemid 30729201)
44. ZAMPINO R., MARRONE A., DURANTE MANGONI E., SANTARPIA L., SICA A., TRIPODI M.F., UTILI R., RUGGIERO G., ADINOLFI L.E. (2004 Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment J. Med. Virol. 73, 33-37. (Pubitemid 38429144)